These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1814871)

  • 21. [Liver tolerance of antitubercular treatment including rifampicin. Study on 214 cases].
    Decroix G; Pujet JC
    Sem Hop; 1973 Jun; 49(30):2219-24. PubMed ID: 4354303
    [No Abstract]   [Full Text] [Related]  

  • 22. Increased incidence of hepatitis induced by isoniazid-rifampin combination in children.
    Thulasimany M
    J Pediatr; 1982 Jan; 100(1):174. PubMed ID: 7057311
    [No Abstract]   [Full Text] [Related]  

  • 23. [Hepatitis caused by drugs. 4].
    Valerdiz Casasola S; Linares Rodríguez A; Recarte Alvarez J; Rodrigo Sáez L
    Rev Esp Enferm Apar Dig; 1982 Oct; 62(4):332-41. PubMed ID: 7163594
    [No Abstract]   [Full Text] [Related]  

  • 24. Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
    Steele MA; Burk RF; DesPrez RM
    Chest; 1991 Feb; 99(2):465-71. PubMed ID: 1824929
    [No Abstract]   [Full Text] [Related]  

  • 25. [Animal experimental studies on the problem of liver damage by antitubercular agents (rifampicin and isoniazide) by means of the galactosamine model].
    Leinweber B; Mahrt R
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():300-3. PubMed ID: 1029192
    [No Abstract]   [Full Text] [Related]  

  • 26. [Icterigenic hepatitis during the treatment with combined isoniazid and rifampicin. Clinical and experimental observations].
    Marche J; Hugues FC; Graisely B; Marche C
    Rev Tuberc Pneumol (Paris); 1971; 35(1):55-76. PubMed ID: 5559725
    [No Abstract]   [Full Text] [Related]  

  • 27. Hepatic dysfunction in tuberculous patients treated with rifampicin and isoniazid.
    Burke M; Logan J
    Ir Med J; 1979 Oct; 72(10):430-4. PubMed ID: 500344
    [No Abstract]   [Full Text] [Related]  

  • 28. [Fulminating hepatitis caused by administration of isoniazid and rifampicin in a patient under chronic treatment with barbiturates].
    Derveaux L; Demedts M; Fevery J; Gyselen A
    Ned Tijdschr Geneeskd; 1980 Jun; 124(25):1008-12. PubMed ID: 7402377
    [No Abstract]   [Full Text] [Related]  

  • 29. [Hepatotoxicity of the combination of isoniazid-rifampicin in African children. Role of malnutrition and HB virus].
    Gendrel D; Nardou M; Mouba JF; Gahouma D; Moussavou A; Boguikouma JB
    Arch Fr Pediatr; 1989 Nov; 46(9):645-8. PubMed ID: 2604523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Determination of adverse reactions of chronic drug therapy as examplified with the hepatotoxic action of isoniazid and rifampicin].
    Bartmann K
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1518-29. PubMed ID: 347784
    [No Abstract]   [Full Text] [Related]  

  • 31. [Isoniazid-rifampicin: a model for hepatotoxicity and for bibliographic Anglomania].
    Toulet J; Viteau JM
    Gastroenterol Clin Biol; 1978; 2(8-9):756-7. PubMed ID: 361483
    [No Abstract]   [Full Text] [Related]  

  • 32. [Monitoring of antitubercular treatments. Value of the determination of serum gamma-glutamyl transpeptidase (gamma-GT)].
    Homasson JP; Salignac P; Bonniot JP; Parent G; Angebault M
    Nouv Presse Med; 1977 Mar; 6(10):858. PubMed ID: 15237
    [No Abstract]   [Full Text] [Related]  

  • 33. [Hepatotoxic side-effects of rifampicin; a comparative clinical study (author's transl)].
    Kuntz HD; Rausch V
    Prax Klin Pneumol; 1977 Nov; 31(11):925-32. PubMed ID: 928291
    [No Abstract]   [Full Text] [Related]  

  • 34. [Liver damage following antituberculous therapy].
    Thaler H
    Dtsch Med Wochenschr; 1982 Jan; 107(3):113. PubMed ID: 7056159
    [No Abstract]   [Full Text] [Related]  

  • 35. Medical grand rounds from Touro Infirmary. Mycobacterium kansasii, aortic stenosis and antimicrobial related hepatitis.
    J La State Med Soc; 1975 Jun; 127(6):227-33. PubMed ID: 1151130
    [No Abstract]   [Full Text] [Related]  

  • 36. Hepatic toxicity of antituberculous drugs in children.
    Allué X; Sanjurjo P; Fidalgo I; Bilbao F
    Helv Paediatr Acta; 1976 Dec; 31(4-5):381-7. PubMed ID: 1017983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Jaundice and rifampicin. Critical study].
    Nebout T; Dhumeaux D; Berthelot P
    Nouv Presse Med; 1974 Mar; 3(12):733-6. PubMed ID: 4836507
    [No Abstract]   [Full Text] [Related]  

  • 38. Hepatotoxicity of rifampin and isoniazid. Is it all drug-induced hepatitis?
    Kumar A; Misra PK; Mehotra R; Govil YC; Rana GS
    Am Rev Respir Dis; 1991 Jun; 143(6):1350-2. PubMed ID: 1904700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PXR-ALAS1: a key regulatory pathway in liver toxicity induced by isoniazid-rifampicin antituberculosis treatment.
    Lyoumi S; Lefebvre T; Karim Z; Gouya L; Puy H
    Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):439-41. PubMed ID: 23916555
    [No Abstract]   [Full Text] [Related]  

  • 40. Hepatotoxicity: pathogenesis and therapeutic intervention.
    Black M
    Clin Gastroenterol; 1979 Jan; 8(1):89-104. PubMed ID: 369749
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.